➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Colorcon
Moodys
McKesson
Baxter

Last Updated: September 16, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022110


Email this page to a colleague

« Back to Dashboard

NDA 022110 describes VIBATIV, which is a drug marketed by Cumberland Pharms and is included in one NDA. It is available from one supplier. There are eleven patents protecting this drug. Additional details are available on the VIBATIV profile page.

The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this compound. Additional details are available on the telavancin hydrochloride profile page.
Summary for 022110
Tradename:VIBATIV
Applicant:Cumberland Pharms
Ingredient:telavancin hydrochloride
Patents:11
Formulation / Manufacturing:see details
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 022110
Generic Entry Date for 022110*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 022110
Suppliers and Packaging for NDA: 022110
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110 NDA Cumberland Pharmaceuticals Inc. 66220-315 66220-315-11 1 VIAL in 1 CARTON (66220-315-11) > 15 mg in 1 VIAL
VIBATIV telavancin hydrochloride POWDER;INTRAVENOUS 022110 NDA Cumberland Pharmaceuticals Inc. 66220-315 66220-315-22 12 VIAL in 1 CASE (66220-315-22) > 15 mg in 1 VIAL

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:POWDER;INTRAVENOUSStrengthEQ 250MG BASE/VIAL
Approval Date:Sep 11, 2009TE:RLD:Yes
Patent:⤷  Free Forever TrialPatent Expiration:Sep 11, 2023Product Flag?YSubstance Flag?YDelist Request?
Patented Use:METHOD FOR TREATING BACTERIAL INFECTION
Patent:⤷  Free Forever TrialPatent Expiration:Aug 24, 2022Product Flag?YSubstance Flag?Delist Request?
Patent:⤷  Free Forever TrialPatent Expiration:Jun 5, 2021Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 022110

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Baxter
Harvard Business School
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.